Clinical trials: Rectal Malignant Neoplasms
Solid Tumors
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential.
- Trial name
- NCT00044785
- Testing
- triacetyluridine, fluorouracil, leucovorin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wellstat Therapeutics
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Neoplasms, Neoplasm Metastasis
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
- Conditions
- Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT02014116
- Testing
- LY3009120 capsule
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Advanced Solid Tumor
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05737706
- Testing
- MRTX1133
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mirati Therapeutics Inc.
Colorectal Neoplasms, Metastases, Neoplasm
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma.
- Trial name
- NCT00044863
- Testing
- Erbitux (Cetuximab)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Cancer
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
The purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned.
- Trial name
- NCT01495663
- Testing
- I-131-CLR1404
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cellectar Biosciences, Inc.
Colonic Polyps, Adenomatous Polyps
ColoMaia II Software to Support Lesion Detection During Colonoscopy
The goal of this clinical trial is to learn whether the ColoMaia II software can help doctors find colon lesions during colonoscopy and whether it is safe to use in adults aged 40 to 80 years having screening, surveillance, or…
- Conditions
- Colonic Polyps, Adenomatous Polyps, Colorectal Neoplasms
- Trial name
- NCT07563816
- Testing
- ColoMaia II software, Standard colonoscopy
- Where
- 3 sites in Czechia
- Volunteers
- 600 people
- Sponsor
- MAIA Labs s.r.o.
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Colorectal Cancer
LYL273 for Patients With Relapsed or Refractory mCRC
This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
- Trial name
- CARABiNER (NCT05319314)
- Testing
- LYL273
- Where
- 5 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lyell Immunopharma, Inc.
Colorectal Neoplasm
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
This is an observational, non-interventional, uncontrolled, multicentric safety study in subjects with epidermal growth factor receptor (EGFR)-expressing, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type…
- Trial name
- NCT01074333
- Testing
- Cetuximab
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Neoplasms, Gastrointestinal Neoplasms
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in…
- Trial name
- NCT06663319
- Testing
- JNJ-89402638, Bevacizumab, FOLFOX
- Where
- 12 sites in United States, South Korea and 1 more
- Volunteers
- 260 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Cancer
Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer
A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.
- Trial name
- NCT00496509
- Testing
- ZD6474 (Zactima) 100mg, Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR), Biomarker Draws
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Metastatic Colorectal Cancer
Trifluridin/tipirACil in MeTastatIc Colorectal Cancer
A non-interventional, prospective, open, multicenter study in Germany in patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies and with…
- Trial name
- TACTIC (NCT03665506)
- Testing
- Trifluridin/Tipiracil
- Where
- Germany
- Volunteers
- 315 people
- Sponsor
- Servier
Colorectal Cancer, Cardiovascular Disease
Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU
In this study researchers want to learn more about the effect of low-dose Aspirin on cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine…
- Conditions
- Colorectal Cancer, Cardiovascular Disease, Bleeding
- Trial name
- PEACOCS (NCT03904732)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- United Kingdom
- Volunteers
- 2,000,000 people
- Sponsor
- Bayer
Colorectal Neoplasms, Diarrhea
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
The study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer.
- Trial name
- NCT00040391
- Testing
- Investigational drug, Irinotecan, 5-fluorouracil
- Where
- 28 sites in United States
- Sponsor
- Celgene Corporation
Metastatic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
- Trial name
- NCT00207155
- Testing
- Cetuximab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Non Small Cell Lung Cancer
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
- Conditions
- Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01059643
- Testing
- LY2523355, pegfilgrastim
- Where
- 18 sites in United States
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC
- Trial name
- NCT04780217
- Testing
- T3011
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- ImmVira Pharma Co. Ltd
Breast Cancer, Colorectal Cancer
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
The primary objectives of this trial are to evaluate the safety and dosimetry of [68Ga]Ga-OncoFAP for detection/imaging of solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Adenocarcinoma
- Trial name
- FAPrimo (NCT05784597)
- Testing
- [68Ga]Ga-OncoFAP administration
- Where
- 5 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Philogen S.p.A.
Colo-rectal Cancer
Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy…
- Trial name
- CASCADE (NCT07148297)
- Where
- Argentina
- Volunteers
- 600 people
- Sponsor
- Epiliquid Holding, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.